Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 3Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1

Conditions

Breast Neoplasms 158Lymphoma 157Precursor Cell Lymphoblastic Leukemia-Lymphoma 130Lymphoma, Non-Hodgkin 120Leukemia 119Leukemia, Lymphocytic, Chronic, B-Cell 116Multiple Myeloma 115Lymphoma, Large B-Cell, Diffuse 100Leukemia, Myeloid, Acute 97Hodgkin Disease 82Myelodysplastic Syndromes 78Lymphoma, Follicular 74Lymphoma, Mantle-Cell 72Burkitt Lymphoma 66Lymphoma, B-Cell, Marginal Zone 52Melanoma 49Leukemia, Myelogenous, Chronic, BCR-ABL Positive 48Neoplasms 45Recurrence 38Hematologic Neoplasms 34Lymphoma, Large-Cell, Immunoblastic 33Myeloproliferative Disorders 31Congenital Abnormalities 31Waldenstrom Macroglobulinemia 30Neoplasms, Plasma Cell 30Leukemia, Myelomonocytic, Chronic 30Lymphoma, B-Cell 29Primary Myelofibrosis 27Lymphoma, Large-Cell, Anaplastic 27Leukemia, Myeloid, Accelerated Phase 26

Interventions

Gemcitabine 14Cisplatin 13Capecitabine 11Paclitaxel 9Oxaliplatin 9Fluorouracil 9130-nm albumin-bound paclitaxel 9pembrolizumab 7Albumin-Bound Paclitaxel 7Ramucirumab 6Leucovorin 6Carboplatin 6Bevacizumab 6Nivolumab 5Irinotecan 5Docetaxel 5Pemetrexed 4Everolimus 4Erlotinib Hydrochloride 4Cyclophosphamide 4trastuzumab deruxtecan 3Radiotherapy 3Afatinib 3zolbetuximab 2trifluridine tipiracil drug combination 2regorafenib 2pralsetinib 2cabozantinib 2Trastuzumab 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma × Cyclophosphamide × Clear all
NCT01088789 2025-08-26

Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Active not recruiting
71 enrolled 13 charts
Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT03153410 2025-01-09

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Completed
11 enrolled 14 charts
Gastrointestinal

Adenocarcinoma, Neoplasms, Pancreatic Neoplasms

NCT03190265 2024-08-07

Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
61 enrolled 11 charts
Gastrointestinal

Adenocarcinoma, Carcinoma, Neoplasms, Pancreatic Neoplasms

NCT03215810 2023-07-24

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
20 enrolled 10 charts
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Recurrence, Carcinoma, Adenosquamous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡